TransUnion (TRU) Sells TransUnion Healthcare to Clearlake Capital's nThrive for $1.7B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Alibaba (BABA) PT Lowered to $165 at Bernstein SocGen Group
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
TransUnion Announces Agreement to Sell TransUnion Healthcare to Clearlake Capital Group-Backed nThrive for $1.7 Billion
October 26, 2021 6:22 AM EDTCHICAGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- TransUnion (NYSE: TRU) has signed a definitive agreement to sell TransUnion Healthcare, Inc. (TransUnion Healthcare) to nThrive, Inc. (nThrive), a leading healthcare revenue cycle management (RCM) software-as-a-service (SaaS) platform backed by Clearlake Capital Group, L.P. (together with certain affiliates, Clearlake).
The transaction consideration is $1.735 billion in cash, and the transaction is expected to result in approximately $1.4 billion in after-tax proceeds at current tax rates. The parties are targeting to close the transaction in the fourth quarter of 2021, subject to the satisfaction of customary closing conditions and regulatory approvals. The... More
